Related Experiment Video
Updated: Jul 17, 2026

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes
Published on: July 7, 2023
PQRI recommendations on particle-size analysis of drug substances used in oral dosage forms
Sharon M Snorek1, John F Bauer, Nallaperumal Chidambaram
1Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana 46285-0001, USA. snorek_sharon_m@lilly.com
Abstract:
This document provides information for the Pharmaceutical Industry and the Federal Drug Administration (FDA) regarding the selection of suitable particle-size analysis techniques, development and validation of particle-size methods, and the establishment of acceptance criteria for the particle size of drug substances used in oral solid-dosage forms. The document is intended for analysts knowledgeable in the techniques necessary to conduct particle-size characterization (a table of acronyms is provided at the end of the document). It is acknowledged that each drug substance, formulation, and manufacturing process is unique and that multiple techniques and instruments are available to the analyst.
Related Concept Videos
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Drug Dissolution: Requirements and Profile Comparison
Precipitate Formation and Particle Size Control
The obtained precipitate should be either a pure substance of known composition or easily converted to one by a simple process, such as ignition or drying. In addition, the precipitate should be insoluble and easily filterable. In general, filterability...
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Biopharmaceutical Factors Influencing Drug Product Design: Overview
